MULTILAYER ENGINEERED HEART MUSCLE

Abstract

A method for manufacturing a multilayer engineered heart muscle that includes (i) providing a liquid reconstitution mixture in a mould and (ii) culturing the mixture. The method includes a sequential addition of one or more further liquid reconstitution mixtures to obtain a multilayer engineered heart muscle. The muscle ideally has the form of a patch, a pouch, or a cylinder. Furthermore, a multilayer engineered heart muscle having collagen, cardiac myocytes and non-myocytes originating from at least 2 layers is disclosed. The multilayer engineered heart muscle forms the basis for several in vitro and in vivo applications such as the production of a multilayer engineered heart muscle for use in a patient, for example for use in heart repair.

Claims

1. A method of manufacturing a multilayer engineered heart muscle (MEHM), the method comprising the steps of: (i) providing a liquid reconstitution mixture in a mould, wherein said reconstitution mixture is perforated by at least two poles, wherein said reconstitution mixture comprises (a) collagen, (b) a cellular mixture of cardiac myocytes and non-myocytes and (c) a suitable reconstitution medium, whereby said reconstitution mixture undergoes gelation in the mould, (ii) culturing the mixture obtained by step (i) in said mould in a suitable culturing medium, whereby the reconstitution mixture compacts in the mould; (iii) a) adding a further liquid reconstitution mixture as defined in step (i) from the top and/or from the bottom to the compacted reconstitution mixture obtained by step (ii) whereby said further liquid reconstitution mixture undergoes gelation, followed by culturing under the same conditions as in step ii), whereby said further reconstitution mixture compacts in the mould; or b) transferring the compacted reconstitution mixture obtained by step (ii) into a different mould, wherein said reconstitution mixture is perforated by at least two poles, followed by carrying out step (iii) a) in said different mould; thereby obtaining a multilayer engineered heart muscle (MEHM), (iv) optionally culturing the MEHM of step (iii) in said mould in a suitable maturating medium, wherein the MEHM is capable of contracting, and wherein the MEHM is from 0.7 mm to 30 mm in thickness.

2. The method of claim 1, wherein an ability of the MEHM to contract is assessed by visual inspection.

3. (canceled)

4. The method of claim 1, wherein the non-myocyte cells are selected from one or more of the group consisting of stromal cells, endothelial cells, smooth muscle cells, and mesenchymal stem cells.

5. The method of claim 1, wherein the MEHM has a form of a patch, a pouch or a cylinder.

6. The method of claim 1, wherein in the gelation in step (i) the reconstitution mixture is opaque.

7. (canceled)

8. The method of claim 1, wherein step (iii)a) or step (iii)b) is repeated 2-200 times.

9. (canceled)

10. A multilayer engineered heart muscle (MEHM) obtained by the method according to claim 1.

11. A multilayer engineered heart muscle (MEHM), comprising (a) collagen and (b) a cellular mixture of cardiac myocytes and non-myocytes, and wherein the MEHM comprises at least 2 layers, and wherein the MEHM is from 0.7 mm to 30 mm in thickness.

12. The MEHM of claim 11, wherein the MEHM has been generated by a repetitive and sequential layering method, wherein the MEHM originates from 2-200 layers, and wherein the layers have been merged to each other and thereby expand the MEHM thickness.

13. The MEHM of claim 11, wherein the cardiac myocytes in the MEHM are sufficiently supplied with oxygen.

14. An in vitro manufacture method of an engineered human myocardium, comprising: assessing a three-dimensional shape of a myocardial defect specific to a patient; manufacturing a MEHM according to the method of claim 1, the MEHM having a three-dimensional shape that matches the three-dimensional shape of the myocardial defect specific to the patient.

15. A method of repairing a heart of a patient, comprising repairing the heart of the patient using the multilayer EHM (MEHM) obtained by the method according to claim 1.

16. The method of claim 1, wherein the MEHM is from 0.9 mm to 20 mm in thickness.

17. The method of claim 1, wherein the poles have a diameter of 0.5 to 3 mm.

18. The method of claim 1, wherein an interpole distance is from 0.1 to 10 mm.

Description

DESCRIPTION OF THE FIGURES

[0277] FIG. 1: Overview of repetitive layering to obtain a multilayer engineered heart muscle (MEHM) as disclosed herein. Generally, the newly added layer (reconstitution mixture) merges to the previous layer (compacted reconstitution mixture). By repetitive layering, a thick and enforced engineered heart muscle is obtained. A “Layering on top” is obtained by adding a new reconstitution mixture on top of the compacted reconstitution mixture. An “Onion pattern” is obtained by immersing the first and consecutively formed stacks of merged layers in newly added reconstitution mixture. A “Layering from the bottom” is obtained by adding a new reconstitution mixture from the bottom to the compacted reconstitution mixture. This layering can be repeated indefinitely considering oxygen and nutrient diffusion requirements of the embedded cells. Oxygen and nutrient supply is achieved by immersion in nutrient (in particular glucose, lactate, and/or fatty acids) containing oxygenated culturing medium and an increased tissue surface area by design, i.e., by the creation of channels via perforating poles (not shown in schematic; refer to FIGS. 2 and 3). The initial first layer is indicated as a dotted line; subsequent layers are indicated in black.

[0278] FIG. 2: Scalability of engineered heart muscle. Photographs depict typical engineered heart muscle formats used by the inventors for disease modelling, drug screening and heart repair. The indicated volumes represent the initial volumes of the respective engineered heart muscle reconstitution mixtures. In a layering approach in order to generate an MEHM as disclosed herein, each reconstitution mixture may have these exemplary volumes. Mechanical loading is realized by the integration of flexible poles into the respective tissue formulations. Geometries and scale can be further adapted as needed. After completion of the self-organization process of one layer EHM thickness (z-dimension) is typically 0.5±0.1 mm in the displayed formulations. By repetitive layering, as disclosed herein, the MEHM is thickened and enforced. Scale bar: 1 cm.

[0279] FIG. 3: Scaling of EHM thickness by sequential/repetitive layering and sufficient supply of oxygen and nutrients. A: Custom-designed casting mould with stretch device (comprised of 3D-printed flexible poles with defined spacing fixed to a solid base plate) to enable the perforated EHM design and facilitate auxotonic contractions of the developing EHM or MEHM against a defined resistance. B: Schematic view of the layered perforated patch design. C: Top and side views of a 5-layered (left) and single-layered (right) EHM; the 5-layered EHM had a thickness of around 5-6 mm and the single-layered EHM has a thickness of around 1 mm. D: By making use of a human ODD-Luc hypoxia reporter iPSC line for the construction of a middle layer in the 5-layered construct (both, the 5-layered and single-layered EHM contain the same amount of ODD-Luc cardiomyocytes, Hesse et al. 2014 for the ODD-Lux hypoxia method), there was no evidence for enhanced hypoxia in the substantially thicker 5-layered design. The gray shade code on the right indicates low and high ODD-Luc activity as a sign of hypoxia sensing. The grey scale depicts luminescence of the reporter cell line. The intensity of the ODD-Luc signal was lower in the 5-layered EHM (left) compared to the background ODD-Luc signal in the single patch (right). In other words, the intensity of the luminescent signal appears to be at least the same in the single-layered EHM compared to the multi-layered EHM, if not brighter in the single-layered EHM. Thus, the 5-layered EHM does not suffer from hypoxia.

[0280] FIG. 4: Multi-well plate format for automated casting in a loop-format. A: custom-made stretchers (flexible poles fixed on a base plate) to support auxotonic contractions of engineered heart myocardium in loop format showing typical dimension of pole dimensions and arrangements. B: Multi-well plate format for automated casting, parallel culture and video-optic analysis of 48 engineered heart myocardium in loop-format with close-up view of a single well showing the cavity for casting and the flexible poles for maturation under defined mechanical loading (please refer to Tiburcy et al. 2020 for addition details)

[0281] FIG. 5: EHM formation in loop-format. A: Automated casting of EHM in a multi-well plate. B: 1 hour after casting, EHM convert to a non-liquid state (collagen gelation results in an opaque appearance of the EHM reconstitution mixture) C: Notable EHM compaction and suspension on flexible poles for mechanical loading 24 hours after casting. D: EHM after completion of compaction on culture day 18 with EHM fully suspended on the flexible poles to impose bi-directional mechanical loading and to support auxotonic contractions under preloaded conditions. Scale bar: 5 mm

[0282] FIG. 6: A: Video-optical Analysis of EHM contraction with or without stimulation. A: Screenshot of the custom-made video-optic analysis tool for functional phenotyping of EHM by fractional area change (FAC) measurements. B: Device for electrical stimulation of EHM to induce contractions at a defined rate. Electrical field stimulation is increased until EHM are induced to contract at a defined beating rate (to typically 2 V/cm). (C) Alternatively, local point stimulation with electrodes touching the EHM can be applied to induce synchronous contractions of EHM for FAC analyses.

[0283] FIG. 7: Multilayer EHM casting moulds in patch format. A: Custom-designed casting mould with two recesses designed to hold a baseplate with poles (bottom) and culture medium (top). In the left recess with flexible poles, a compacted reconstitution mixture is depicted for clarification. Layers are stacked on top, inserted below or formulated around the first layer. B: Cross section thought recess in casting mould with vertically, perforating poles (grey and white) with layered EHM in black. C: Examples for pole designs with and without pole thickness gradient; note that by design of the poles (elastic properties, diameter or geometry of poles) homogeneous (no gradient, all poles are 0.9 mm in diameter in this example) and heterogeneous (example of a top to bottom gradient, poles have a diameter from 1.1 mm to 0.7 mm from top to bottom with 0.1 mm steps) mechanical loading imposed on the EHM can be controlled. D: Example of an EHM, which developed either isotropic (no gradient; wherein the poles have the same diameter) or anisotropic (vertical gradient; wherein the poles a gradient in diameter) contraction patterns. Contraction patterns are analysed by comparing the FAC of the upper and the lower part of the EHM. When all poles have the same diameter, the upper and the lower part of the EHM showed a similar contraction of around 1% FAC. In contrast, a vertical gradient lead to an increase in contraction force of the upper part to around 1.2% FAC (larger pole diameter) and lead to a decrease in contraction force of the lower part to around 0.7% FAC (smaller pole diameter).

[0284] FIG. 8: Multilayer engineered heart muscle (MEHM) in variable geometries. Examples for multilayer engineered heart muscle (MEHM) designs. MEHM can be produced in pouch (A), cylinder (B), and patch formats (C) with variable thickness and x-y-dimensions (exemplified in patch format in C). In the MEHM pouch geometry (A), MEHM are cast in a circular or spherical mold with a central element (solid or flexible for biomechanical loading of the compacting EHM; similar as described in Zimmermann W H, Yildirim Y, Eschenhagen T: Pouch-like engineered heart muscle tissue. WO2008058917 and Yildirim et al. (2007) Circulation). In the depicted example, interpole distance is 3.5 mm with a pole diameter of 1.5 mm in analogy to a preferred embodiment described for EHM patches (FIG. 7). Poles can be adapted in size, geometry, and interpole distance as needed to create optimal loading and perforation for oxygen and nutrient supply. In case of the cylinder geometries (B), poles can be fabricated to point inwards or outwards and with wholes preferably in the cylinders with the outwards pointing poles. Layering can be supported by centrifugal forces (>2 g; “spin-coating”) induced by controlled rotation. (C) Heterogeneous (“patch-in-patch”) multi-layer strategies either by positioning of a perforated patch assembly is demonstrated, including the perforating pole element, into a new mould to accommodate additional layering (C1) or by making use of inserts to isolate a defined casting volume within a larger casting mold design (C2). This allows for a free design of MEHM with variable thickness and xy-dimensions to facilitate the fabrication of a patient heart matched/individualized patch.

EXAMPLES

[0285] The following examples are intended to illustrate the invention further, but are not limited to it. The examples describe technical features, and the invention also relates to combinations of the technical features presented in this section.

Example 1—Scalable Production of Engineered Heart Muscle (EHM) in Loop-Format and Patch Format

[0286] As previously described by the inventors in Tiburcy et al. (2017) and Tiburcy et al. (2020), engineered human myocardium can be produced in a loop format and as patches. In particular for the in vivo use for heart repair, the engineered heart patches is of prime importance. FIG. 2 provides an overview, of different sizes and formats, which have been produced and published previously (Tiburcy et al. (2017) and Tiburcy et al. (2020)).

Example 2—Scaling of EHM Thickness by Sequential and Repetitive Layering Supported by Perforating Poles Ensuring Mechanical Loading and Sufficient Supply of Oxygen and Nutrients

[0287] For the production of heart muscle for the treatment of patients with heart failure, an engineered heart muscle ideally needs to support the force of a beating human heart. The cardiac wall to be treated is typically 5-10 mm thick in the patient, i.e., an implant ideally reaches this thickness and is geometrically adaptable to meet the specific patient demands for mechanical support of the underperforming heart wall.

[0288] In order to generate a thickened (and enforced) multilayer EHM, the inventors developed a sequential and repetitive layering method. Specifically, FIG. 1 shows three different ways of repetitive and sequential layering in order to obtain a thickened engineered heart patch (note that for simplification perforating poles are excluded). As a general principle, the first reconstitution mixture, after compaction to a defined layer, is coated by additional reconstitution mixtures. Coating can be from the top, from the bottom, or from both sides as schematically shown in FIG. 1. The process is repeated until the desired tissue thickness is achieved. By design of the casting mould, any shape and desired x-y dimensions can be created (individualized patch design). A prerequisite for the coating/layering process is that the first and subsequently produced layers form a compact tissue. This compact tissue formation is achieved by repetitive and sequential layering as the individual reconstitution mixtures merge to each other. Tissue compaction is a function of the stroma cell type and content (Tiburcy et al. (2017), Schlick et al. (2019)). Stroma cell type and content are chosen to reach 20°/o compaction of the original reconstitution mixture (FIG. 5B-C demonstrates the EHM compaction in exemplarily in a loop format). This provides the structure and physical space to coat the compacting EHM with a further layer from the top and/or the bottom or a both surface coating layers. The inventors typically add new layers 24 h after casting of the previous layer. These times can be shortened or extended as desired and experimentally determined, as the desired tissue compaction process is dependent on the stroma cell type and density, the cell composition in general, and the hydrogel and culture medium composition (e.g., addition of effective TGFb1 concentrations can accelerate the process as exploited in Tiburcy et al. (2017) and WO2017/207431 for the formation of EHM). Further reconstitution mixtures may be added to the mould in order to coat the compacted, multi-layer engineered heart muscle. By performing this method, the EHM thickens layer-by-layer, so that a multi-layered EHM can reach the clinically desired thickness of 5 mm to 10 mm or even beyond. As the thickness of a human cell wall is between 5 mm to 10 mm, it is assumed that such a thickened heart patch is also able to sustain enough mechanical stability to support cardiac wall function. Furthermore, it is expected that the contractility of the cardiomyocytes embedded within the EHM support the contraction of the natural heart.

[0289] FIG. 3A depicts a casting mould with stretch device (comprised of 3D-printed flexible poles with defined spacing fixed to a solid removable base plate) to enable the perforated EHM design and facilitate auxotonic contractions of the developing patch against a defined resistance. Of course, the size of the casting mould as well as the number of poles and the size of the poles can be adapted. FIG. 3B shows a schematic overview of a multi-layered EHM as disclosed herein. In FIG. 3C, a generated 5-layered EHM and a single-layered EHM is shown next to each other. In the lower panel of FIG. 3C, the thickness of the EHM is compared specifically demonstrating that a 5-layered EHM is approximately 5-6 millimetres in thickness. By use of the introduced perforated layering design there is no limitation in overall tissue thickness with constant diffusion distances as a result of the channels produced by the perforating poles. Of course, pole distance and size can be adapted to increase channel number and alter channel size and inter-channel distance.

[0290] A key challenge in trying to obtain such a thick multilayer engineered heart muscle (MEHM) is to ensure the supply of oxygen and nutrients to the cells embedded in the engineered heart muscle. By the perforated EHM design, the inventors ensure a sufficient oxygen and nutrient supply in any given multilayer design. This is exemplified by studies of the inventors using a human ODD-Luc hypoxia reporter model (developed by the inventors based on previous experience in a mouse model; Hesse et al. (2014)). Cardiomyocytes derived from an ODD-Luc human pluripotent stem cell line in a single and 5-layer (5-6 mm thick) did not show differences in ODD-Luc signal intensity above background (reported in the single layer EHM). Channel diameter and density in the demonstrated EHM design was defined by pole diameter (1.5 mm) and pole circumference-to-circumference distance (3.5 mm). Under these conditions (effective maximal surface distance in the EHM is ≤1.75 mm) no hypoxia was observed. The perforated patch format contrasts the vascular density in the human heart (2.000-5.000 capillaries/mm.sup.2, with an intercapillary distance of <25 μm). It was therefore surprising and also in contrast to theoretic assumptions that oxygen supply by diffusion over a distance of >100 μm would result in the sensing of hypoxic conditions by cardiomyocytes (Radisic et al. (2005). This discrepancy can be explained by the high hypoxia resistance in pluripotent stem cell derived cardiomyocytes in the presence of nutrient (glucose, lactate, and/or fatty acids)-containing culture medium.

[0291] By performing repetitive and sequential layering as well as in particular the perforated patch design, it is ensured that the cells within the EHM do not suffer from hypoxia and are supplied with enough nutrients. Another theoretical option of generating a thickened EHM of e.g. 10 mm would be to directly cast a large volume of reconstitution mixture in one casting step. In order to obtain an EHM of 10 mm in thickness, the single reconstitution mixture would need to be around 100 mm in thickness. The cells within said mixture would need to be supplied with oxygen and nutrients over a 1 to 10 centimetre distance depending on the stage and extent of tissue compaction. As the EHM is not vascularized, the embedded cells would suffer from hypoxia induced apoptosis and necrosis in centimetre scale EHM. In order to overcome this hurdle, the inventors have developed a method to perform repetitive and sequential layering in casting moulds equipped with perforating poles (FIGS. 3 and 7), as disclosed herein. This approach is advantageous over other approaches, which do not ensure sufficient oxygen and nutrient supply.

[0292] Furthermore, it is essential that the penetrating poles install mechanical support elements to support auxotonic contractions.

Materials and Methods of Example 2

[0293] Generation of 5-layered EHM: EHM were constructed in custom-made casting moulds (FIG. 7) using a reconstitution mixture described in Tiburcy et al. (2017) and WO2015025030. After casting of the reconstitution mixture (8 mL; refer to FIG. 2) EHM compaction was observed within 3 days to less than 50% of the original reconstitution volume. After removal of the culturing medium, a second layer (comprised of 6 mL reconstitution mixture—volume may be adjusted and depends on mould design/surface area and use, and can be adapted according to EHM compaction) was pipetted into the casting mould to cover the compacted EHM from the top and the bottom. For example, 8 ml could have also been also added or a smaller volume such as 2 ml for covering a restricted area (see Example 5 for further illustration). After approximately 1 h, gelation of the newly pipetted reconstitution mixture was completed and culturing medium was added to the mould. This process was repeated until 5 layers were obtained. Reconstitution mixture volume for repetitive layering and timing depends on casting mould dimensions and stroma-cell mediated compaction of the EHM.

[0294] Generation of a hypoxia reporter line. A piggyBAC-ODD-Luc plasmid was cloned that contains firefly luciferase fused to the oxygen-dependent degradation domain (ODD) of HIF1a under control of the chicken actin promotor (CAG). Under normoxic conditions the ODD domain is rapidly degraded by the ubiquitin-proteasome system. Under hypoxia the ODD domain is stabilized leading to measurable luminescence (Hesse et al. (2014)). TC1133 iPSC were electroporated with piggyBAC—ODDLuc constructs together with a transposase vector. 48 hrs after electroporation cells were selected with increasing concentration of Neomycin (250-500-750 ug/mL) for 7 day before colonies were manually picked and expanded.

[0295] Validation of the hypoxia reporter line. Pluripotent stem cells expressing firefly luciferase fused to the oxygen-dependent degradation domain (ODD) of HIF1a under control of the chicken actin promotor (CAG) were lysed in 1× Passive lysis buffer (Dual-Luciferase® Reporter Assay Systems, Promega) with protease and phosphatase inhibitors (both Roche) after being exposed to hypoxia (5 or 1% O.sub.2). Cell-containing or cell-free (lysis buffer only) lysates were mixed with Luciferase assay reagent II (Dual-Luciferase® Reporter Assay Systems, Promega) and luminescence was measured using a FlexStation 3 Multi-Mode Microplate Reader (Molecular Devices); mean±SEM; n=3:

TABLE-US-00001 Cell-free Cells Oxygen concentration 21% 21% 5% 1% Luminescence (RLU, × 10E3) 40 ± 4 216 ± 6 3300 ± 90 9380 ± 400

[0296] The increase in luminescence signal from the stably genetically integrated ODD-Luc reporter in response to lower oxygen concentrations demonstrated the utility of the ODD-Luc model in the sensing of hypoxia in human pluripotent stem cell models.

[0297] Bioluminescence imaging of hypoxia reporter EHM. ODD-Luc EHM were submerged in phosphate buffered saline containing 1 mg/ml XenoLight D-Luciferin (Perkin Elmer). Luminescence of EHM was imaged at 37° C. using an IVIS Lumina III system (Perkin Elmer). Luminescence is represented in grey scale in FIG. 3D. The 5-layered EHM showed less luminescence than the single-layered EHM.

Example 3— Generation of EHM in Loop-Format in a Multi-Well Plate Illustrating the Condensation Process of Engineered Human Myocardium

[0298] FIG. 5 provides a proof-of-principle overview of the condensation (after 1 h of gelation) and compaction (after 24 h and 18 days) of the reconstitution mixture in order to form a force-generating EHM in loop-format. For example, EHM in loop format can be generated on custom-made stretchers (flexible poles fixed on a base plate) to support auxotonic contractions of engineered human myocardium (FIG. 4A). As previously disclosed in Tiburcy et al. (2020), 48 EHMs in loop-format can be produced in parallel by using a defined multi-well plate (FIG. 4B). The multi-well plate is also further described in WO 2017/207431. The multi-well plate is characterized in that each mould is in the form of a ring channel. Each EHM is cast into a ring channel. During condensation and compaction of the reconstitution mixture, the engineered human myocardium detaches from the ring channel, moves upwards and closely wraps around the two poles.

[0299] In a first step, the reconstitution mixture was provided in the mould of the multi-well plate as described previously in Tiburcy et al. 2017 or Tiburcy et al. 2020. When the reconstitution mixture is cast into the mould, the reconstitution mixture is a viscous liquid translucent solution. After one hour of incubation at 37° C. in a humidified incubator with 5% CO.sub.2, the engineered human myocardium turned opaque as the reconstitution mixture consolidated primarily by cell-independent gelation of the collagen hydrogel (refer also to Tiburcy et al. (2014), Schlick et al. (2019)). After consolidation (for e.g. 1 hour, FIG. 5B), culturing medium was added to the moulds, which provided nutrients and growth factors (see e.g. Tiburcy et al. (2017) and Tiburcy et al. (2020) for exemplary medium compositions). After culturing for e.g. 24 hours, the loop detached from the mould so that a space between the reconstitution mixture and the mould was visible. Furthermore, after 24 hours, the reconstitution mixture detached from the ring channel and closely wrapped around the two poles (FIG. 5C). The process of EHM formation around the flexible poles is a function of the stroma cell component and can further be facilitated by addition of effective concentrations of TGFb1. After engineered human myocardium are positioned on the flexible poles engineered human myocardium maintenance medium without TGFb1 was used. In the following 17 days, the mixture further condenses around the two poles as depicted in FIG. 5D and a compact and contracting engineered human myocardium develops. The poles are developed to bend in response to the EHM contractions and to pull the EHM apart to a defined resting length during the EHM relaxation phase to simulate the natural auxotonic contraction cycles of the heart.

Example 4—Excitability of Engineered Heart Muscle (EHM)

[0300] Excitation of cardiomyocytes typically leads to a contraction of these cells. In order to measure the contraction within EHMs, Tiburcy et al. (2017) described the fractional area change (FAC) of the patch upon contraction. FAC is a video-optical measurement, wherein the surface area of the patch is compared in a non-contracted and contracted state. By using said videooptic analysis tool, EHMs can be phenotyped and compared. FIG. 6A depicts a custom-made video-optic analysis tool in order to facilitate the measurement. FIG. 6B shows a device for electrical stimulation of EHM to induce contractions at a defined rate. Electrical field stimulation strength is increased (to typically 2 V/cm.sup.2) until EHM are induced to contract at a defined beating rate (typically controlled at 0.1-3 Hz). Alternatively, local point stimulation with electrodes touching the EHM can be applied to induce synchronous contractions of EHM at a desired beating rate for FAC analyses (FIG. 6C).

[0301] FAC (fraction area change) is measured by comparing the EHM surface area upon video-optic imaging in maximal systole (maximally contracted state) and maximal diastole (maximally relaxed state). The change in surface area is recorded as function of time.

Example 5—Various Geometries for Multilayer Engineered Heart Muscle Designs

[0302] In general, MEHM can be generated in various three-dimensional shapes. The general principle is a mould equipped with perforating poles with homogeneous or heterogeneous shapes and dimensions to (i) impose mechanical resistance on the forming EHM and (ii) to create perforating channels for nutrient and oxygen supply. In the EHM pouch geometry (as depicted in FIG. 8A), EHM are cast in a circular or spherical mold with a central element (solid or flexible for biomechanical loading of the compacting EHM; similar as described in Zimmermann W H, Yildirim Y, Eschenhagen T: Pouch-like engineered heart muscle tissue. WO2008058917 and Yildirim et al. (2007) Circulation). In contrast to WO2008058917 and to reliably create, e.g. >1 mm, thick pouches with controlled muscle formation, perforating poles are created on top of the central element. In the depicted example of FIG. 8A, interpole distance is 3.5 mm with a pole diameter of 1.5 mm in analogy to a preferred embodiment described for EHM patches (FIG. 7). Poles can be adapted in size, geometry, and interpole distance as needed to create optimal loading and perforation for oxygen and nutrient supply.

[0303] In a further example, the MEHM can also have the form of a cylinder. In case of the cylinder geometries (FIG. 8B), poles can be fabricated to point inwards or outwards so that the reconstitution mixture is perforated. A key advantage of a cylindrical shaped EHM is that many EHMs can be produced on parallel using up comparatively little space. After completion of the cylindrical MEHM production, the MEHM can be sliced open on one side in order to obtain a patch or left intact to yield a MEHM cylinder/tube of desired dimensions. The MEHM dimensions can be scaled by freely adapting the circumference of the inner and/or outer mould cylinders with poles extending/radiating inwards or outwards. Moulds in the form of cylinders with perforating poles are produced for example by protoype 3D-printing to fit into a container. Said container then supplies the outer wall for cylindrical EHM production (for example 50 ml polypropylene or glass tube). The container is filled with sufficient reconstitution mixture to coat the inner or outer side of the cylinder. Layering can be supported by centrifugal forces (>2 g; “spin-coating”) induced by controlled rotation. Tubular/cylindrical EHM generated in cylindrical, longitudinally spinning bioreactors should be performed at >2 g. Inserted tubular stretcher contain radially extruding poles to perforate EHM. Centrifugal force experienced by EHM can be controlled by adjusting rotation velocity to mimic increasing diastolic pressure during maturation. Furthermore, centrifugation ensures an equal spreading of the reconstitution mixture in order to ensure an equal thickness of the EHM. Equal coating in an outward radiating cylinder design can be further improved by using an inner mould cylinder with wholes to allow for equal distribution of the reconstitution mixture during a spin coating procedure. After coating and gelation, culturing medium can be added to facilitate compaction. The multilayering can be repeated until the desired layer composition is achieved. Layers can be added to the top and/or the bottom of the previous reconstitution mixture.

[0304] FIG. 8C demonstrates a further example of MEHM design. FIG. 8C shows heterogeneous (“patch-in-patch”) multilayer strategies to create MEHM with variable thicknesses according to the needed in the production of individualized MEHM for example for clinical use in heart repair: Firstly, by positioning of a perforated patch assembly into a new mould to accommodate additional layering (C1), and secondly by making use of inserts to isolate a defined casting volume within a larger casting mold design (C2). This allows for a free design of EHM with (i) variable thickness and (ii) xy-dimensions to facilitate the fabrication of a patient heart matched/individualized patch. The described elements can be prepared by prototype 3D printing as described in Tiburcy et al. (2017), cast molding, or other suitable engineering methods. Moulds are typically created from teflon, PDMS, or agarose using milling or cast molding whereas the perforated pole assemblies are typically printed using 3D printing, for example with a Connex350 (Stratasys) 3D printer, or by cast molding. For 3D printing, a biocompatible MED610 polymer for stiff components (for example base plate in case of the perforated patch design or the outer mould elements of the pouch-design) in combination with a TangoBlack polymer for the flexible elements, such as the poles and cylinders, can be applied.

Tables

[0305]

TABLE-US-00002 TABLE 1 Composition of the serum-free supplement `B27 minus insulin' (50x concentration, liquid) 20 ml of 'B27 minus insulin' per 500 ml medium corresponds to 4% B27 minus insulin (v/v); final concentration in concentration in B27 medium Ingredients μg/ml μg/ml Bovine serum albumin, fraction V IgG free, 125000 5000 fatty acid poor Catalase 125 5 Glutathion reduced 50 2 Superoxide Dismutase 125 5 Humanes Holo-Transferrin 250 10 T3 (triodo-I-thyronine) 0,1 0,004 L-carnitine-HCl 100 4 Ethanolamine 50 2 D + -galactose 750 30 Putrescine 805 32,2 sodium-Selenite 0,625 0,0250 Corticosterone 1 0,04 linoleic acid 50 2 linolenic acid 50 2 Progesterone 0,315 0,0126 Retinylacetate 5 0,2 DL -alpha tocopherole (Vit E) 50 2 DL-alpha tocopherol Acetate 50 2 Biotin 125 5

LIST OF REFERENCES

[0306] EP2099508 [0307] EP20188364.2 [0308] EP2842581 A1 [0309] EP2840132 B1 [0310] WO 2007/054286 [0311] WO 2008/058917 A1 [0312] WO 2015/025030 [0313] WO 2017/207431 [0314] Bao X, et al. Long-term self-renewing human epicardial cells generated from pluripotent stem cells under defined xeno-free conditions. Nat Biomed Eng. 2016; 1; or [0315] Bao X, et al. Directed differentiation and long-term maintenance of epicardial cells derived from human pluripotent stem cells under fully defined conditions. Nat Protoc. 2017 September; 12(9):1890-1900. [0316] Brewer, G. J., Torricelli, J. R., Evege, E. K. and Price, P. J. (1993), Optimized survival of hippocampal neurons in B27-supplemented Neurobasal™, a new serum-free medium combination. J. Neurosci. Res., 35: 567-576. Fujita N, Duerinekx A J, Higgins C B. Variation in left ventricular regional wall stress with cine magnetic resonance imaging: normal subjects versus dilated cardiomyopathy. Am Heart J. 1993 125:1337-45. [0317] Hanses, U., Kleinsorge, M., Roos, L., Yigit, G., Li, Y., Barbarics, B., El-Battrawy, I., Lan, H., Tiburcy, M., Hindmarsh, R., et al. (2020). Intronic CRISPR Repair in a Preclinical Model of Noonan Syndrome-Associated Cardiomyopathy. Circulation [0318] Hesse A R, Levent E, Zieseniss A, Tiburcy M, Zimmermann W H, Katschinski D M (2014) Lights on for HIF-1α: Genetically Enhanced Mouse Cardiomyocytes for Heart Tissue Imaging. Cell Physiol Biochem. 34:455-462 [0319] Hynes R O, Naba A. Overview of the matrisome—an inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol. 2012; 4(1):a004903. [0320] Ieda M, Fu J D, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau B G, Srivastava D. Direct reprogramming of fibroblasts into func-tional cardiomyocytes by defined factors. Cell. 2010 Aug. 6; 142(3):375-86. Iyer D, et al. Robust derivation of epicardium and its differentiated smooth muscle cell progeny from human pluripotent stem cells. Development. 2015 Apr. 15; 142(8):1528-41; [0321] Iyer R K, Radisic M, Cannizzaro C, Vunjak-Novakovic G. Synthetic oxygen carriers in cardiac tissue engineering. Artif Cells Blood Substit Immobil Biotechnol. 2007; 35(1):135-48. [0322] Kawel N, Turkbey E B, Carr J J, Eng J, Gomes A S, Hundley W G, Johnson C, Masri S C, Prince M R, van der Geest R J, Lima J A, Bluemke D A. Normal left ventricular myocardial thickness for middle-aged and older subjects with steady-state free precession cardiac magnetic resonance: the multi-ethnic study of atherosclerosis. Circ Cardiovasc Imaging. 2012 July; 5(4):500-8. [0323] Kensah, G., Roa Lara, A., Dahlmann, J., Zweigerdt, R., Schwanke, K., Hegermann, J., Skvorc, D., Gawol, A., Azizian, A., Wagner, S., et al. (2013). Murine and human pluripotent stem cell-derived cardiac bodies form contractile myocardial tissue in vitro. Eur Heart J 34, 1134-1146 [0324] Mills, R. J., Parker, B. L., Quaife-Ryan, G. A., Voges, H. K., Needham, E. J., Bornot, A., Ding, M., Andersson, H., Polla, M., Elliott, D. A., et al. (2019). Drug Screening in Human PSC-Cardiac Organoids Identifies Pro-proliferative Compounds Acting via the Mevalonate Pathway. Cell Stem Cell 24, 895-907 e896. [0325] Mouw J K, Ou G, Weaver V M. Extracellular matrix assembly: a multiscale deconstruction. Nat Rev Mol Cell Biol. 2014; 15(12):771-785. doi:10.1038/nrm3902 [0326] Mulieri L A, Hasenfuss G, Leavitt B, Allen P D, Alpert N R. Altered myocardial force-frequency relation in human heart failure. Circulation. 1992 May; 85(5):1743-50. [0327] Nam Y J, Song K, Luo X, Daniel E, Lambeth K, West K, Hill J A, DiMaio J M, Baker L A, Bassel-Duby R, Olson E N. Reprogramming of human fibroblasts toward a cardiac fate. Proc Natl Acad Sci USA. 2013 Apr. 2; 110(14):5588-93. [0328] Nowosielski M, Schocke M, Mayr A, Pedarnig K, Klug G, KOhler A, Bartel T, Müller S, Trieb T, Pachinger O, Metzler B. Comparison of wall thickening and ejection fraction by cardiovascular magnetic resonance and echocardiography in acute myocardial infarction. J Cardiovasc Magn Reson. 2009 Jul. 9; 11(1):22. [0329] Naito, H., Melnychenko, I., Didie, M., Schneiderbanger, K., Schubert, P., Rosenkranz, S., Eschenhagen, T., and Zimmermann, W. H. (2006). Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle. Circulation 114, 172-78 [0330] O'Leary L E, Fallas J A, Bakota E L, Kang M K, Hartgerink J D. Multi-hierarchical self-assembly of a collagen mimetic peptide from triple helix to nanofibre and hydrogel. Nat Chem. 2011 Aug. 28; 3(10):821-8. doi: 10.1038/nchem.1123. PMID: 21941256. [0331] Pislaru C, Urban M W, Pislaru S V, Kinnick R R, Greenleaf J F. Viscoelastic properties of normal and infarcted myocardium measured by a multifrequency shear wave method: comparison with pressure-segment length method. Ultrasound Med Biol. 2014 August; 40(8):1785-95 [0332] Radisic M, Deen W, Langer R, Vunjak-Novakovic G. Mathematical model of oxygen distribution in engineered cardiac tissue with parallel channel array perfused with culture medium containing oxygen carriers. Am J Physiol Heart Circ Physiol. 2005 March; 288(3):H1278-89 [0333] Riegler, J., Tiburcy, M., Ebert, A., Tzatzalos, E., Raaz, U., Abilez, O. J., Shen, Q., Kooreman, N. G., Neofytou, E., Chen, V. C., et al. (2015). Human Engineered Heart Muscles Engraft and Survive Long Term in a Rodent Myocardial Infarction Model. Circulation research 117, 720-730 [0334] Ronaldson-Bouchard, K., Ma, S. P., Yeager, K., Chen, T., Song, L., Sirabella, D., Morikawa, K., Teles, D., Yazawa, M., and Vunjak-Novakovic, G. (2018). Advanced maturation of human cardiac tissue grown from pluripotent stem cells. Nature 556, 239-243 [0335] Rump, J., Klatt, D., Braun, J., Warmuth, C. and Sack, I. (2007), Fractional encoding of harmonic motions in MR elastography. Magn. Reson. Med., 57: 388-395 [0336] Schlick S F, Spreckelsen F, Tiburcy M, Iyer L M, Meyer T, Zelarayan L C, Luther S, Parlitz U, Zimmermann W H, Rehfeldt F. Agonistic and antagonistic roles of fibroblasts and cardiomyocytes on viscoelastic stiffening of engineered human myocardium. Prog Biophys Mol Biol. 2019 July; 144:51-60. [0337] Song K, Nam Y J, Luo X, Qi X, Tan W, Huang G N, Acharya A, Smith C L, Tallquist M D, Neilson E G, Hill J A, Bassel-Duby R, Olson E N. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature. 2012 May 13; 485(7400):599-604. [0338] Soong P L, Tiburcy M, and Zimmermann (2012) Cardiac differentiation of human embryonic stem cells and their assembly into engineered heart muscle. Curr Protoc Cell Biol. Chapter 23:Unit23.8. [0339] Stoker M E, Gerdes A M, May J F. Regional differences in capillary density and myocyte size in the normal human heart. Anat Rec. 1982 February; 202(2):187-91. [0340] Tulloch N L, Muskheli V, Razumova M V, et al. (2011) Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res 109(1):47-59. [0341] Tiburcy M, Meyer T, Soong P L, Zimmermann W H. Collagen-based engineered heart muscle. Methods Mol Biol. 2014; 1181:167-76. doi: 10.1007/978-1-4939-1047-2_15. PMID: 25070336. [0342] Tiburcy, M., Hudson, J. E., Balfanz, P., Schlick, S., Meyer, T., Chang Liao, M. L., Levent, E., Raad, F., Zeidler, S., Wingender, E., et al. (2017). Defined Engineered Human Myocardium With Advanced Maturation for Applications in Heart Failure Modeling and Repair. Circulation 135, 1832-1847. [0343] Tiburcy, M., Meyer, T., Liaw, N.Y., and Zimmermann, W. H. (2020). Generation of Engineered Human Myocardium in a Multi-well Format. STAR Protocols. [0344] Wiegerinck R F, Cojoc A, Zeidenweber C M, Ding G, Shen M, Joyner R W, Fernandez J D, Kanter K R, Kirshbom P M, Kogon B E, Wagner M B. Force frequency relationship of the human ventricle increases during early postnatal development. Pediatr Res. 2009; 65:414-419. [0345] Weinberger F, Breckwoldt K, Pecha S, et al. (2016) Cardiac repair in guinea pigs with human engineered heart tissue from induced pluripotent stem cells. Sci Transl Med 8(363):363ra148. [0346] Witty A D, Mihic A, Tam R Y, et al. Generation of the epicardial lineage from human pluripotent stem cells. Nat Biotechnol. 2014; 32(10):1026-1035; [0347] Yildirim Y, Naito H, Didie M, Karikkineth B C, Biermann D, Eschenhagen T, Zimmermann W H. Development of a biological ventricular assist device: preliminary data from a small animal model. Circulation. 2007 Sep. 11; 116(11 Suppl):I16-23. [0348] Zhang, D., Shadrin, I. Y., Lam, J., Xian, H. Q., Snodgrass, H. R., and Bursac, N. (2013). Tisis sue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. Biomaterials 34, 5813-5820 [0349] Zimmermann W H, Melnychenko I, Wasmeier G, et al. (2006) Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med 12(4):452-8.